Skip to main content

Psychedelics Business

Psychedelics Business
Aion Therapeutic has announced the opening of the Aion International Center for Psychedelic Psychiatry, a Jamaica-based facility that will specialize in the use of psilocybin in treating addiction, depression, major depressive disorder, and other mental health conditions.
Psychedelics Business
Ahead of a U.S. public offering, atai Life Sciences, a biopharmaceutical firm developing psychedelic and non-psychedelic compounds for mental health disorders, announced on Wednesday that it has closed a $157 million Series D round of financing.
Psychedelics Business
Earlier this month, ATMA Journey Centers opened ATMA Calgary Urban Journey Clinic, the first non-ketamine psychedelic therapy clinic in Canada.
Psychedelics
Ronan Levy, co-founder and executive chairman of Field Trip Health, joins the BHE Podcast to discuss transitioning from practicing law to entrepreneurship endeavors that challenge the status quo, surging interest in the therapeutic potential of…
Psychedelics Business
Field Trip Health has announced the opening of a psychedelic therapy treatment center in Atlanta, expanding the company's growing portfolio of U.S. facilities that also includes locations in New York, Los Angeles and Chicago.
Psychedelics Business
Former NHL player Daniel Carcillo has founded Wesana Health, an emerging life sciences company that will focus on developing psychedelic-assisted therapies to treat traumatic brain injuries.
Psychedelics Business
atai Life Sciences, a clinical-stage biopharmaceutical firm backed by Peter Thiel and other investors, recently acquired a majority stake in Recognify Life Sciences. The company is also planning an IPO, per a media report.
Psychedelics
Following the announcement of new executives and plans for a translational research program on the use of psychedelics in the treatment of physical and psychological pain, Mind Cure is acquiring an ownership interest in psychedelic-assisted therapy provider ATMA Journey Centers.
Psychedelics Business
COMPASS Pathways and the Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics announced that the two organizations are collaborating on a “Centre of Excellence” that will serve as a research facility and innovation lab for the development of mental healthcare therapy models, a training and certification ground for therapists, and hub for conducting clinical trials.
Psychedelics Business
Novamind, a Toronto-based mental health company that specializes in psychedelic-assisted therapy, announced that common shares of the company were to begin trading on the Canadian Securities Exchange on Tuesday.
Back to Top